All In Biotech

Drug Trial Radar · NCT06508021

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Oct 25, 2024

Primary completion

Feb 4, 2029

Study completion Feb 4, 2029

Sponsor

Lead sponsor
Ashibio IncIndustry
Sponsor type
Industry
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO) * Whether andecaliximab reduces the number or severity of flare-ups * Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s) * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Fibrodysplasia Ossificans Progressiva

Interventions

  • AndecaliximabDrug

    Dose level A or B

  • PlaceboDrug

    Blinded

  • AndecaliximabDrug

    Dose level A or B (or age adjusted dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]Time frame: Week 27 and 53

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco (UCSF)

    San Francisco, California

  • Mayo Clinic

    Rochester, Minnesota

  • University of Pennsylvania - Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.